Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal Sinus
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorEye & ENT Hospital of Fudan University
About this trial
Soft tissue sarcoma (STS) refers to a group of malignant tumors derived from non-epithelial extraosseous tissues, mainly from the mesoderm, partly from the neuroectoderm, including muscle, fat, fibrous tissue, blood vessels and peripheral nerves . STS is divided into 12 major categories based on tissue origin. According to different morphologies and biological behaviors, there are more than 50 subtypes. The most common subtypes include: undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), leiomyosarcoma (LMS), synovial sarcoma ( SS). The most common soft tissue sarcoma in children and adolescents is rhabdomyosarcoma (RMS). Soft tissue sarcoma is a group of highly heterogeneous tumors, which are characterized by local invasiveness, invasive or destructive growth, local recurrence and distant metastasis.
The pathological features of STS that occur in the nasal cavity and sinuses are similar to other parts of the body. However, because it can affect important structures such as the orbit, optic nerve, skull base bone, dura mater, cranial nerve and even brain tissue, the diseased site is deep, the anatomical structure is complex, the treatment is difficult, the range of surgical resection is limited, and the surgical margin Negative is difficult to guarantee, and related treatments may have obvious complications, which affect the survival and prognosis of patients.
Surgical treatment is the most important and most likely effective treatment for STS. With the development of endoscopic skull base anatomy and surgical techniques, the safety and effectiveness of endoscopic sinus surgery for the treatment of nasal cavity and sinus tumors have been fully confirmed, and it has become the main surgical method for nasal cavity and sinus STS. This is also the theoretical and practical basis for the feasibility of this research.
The study intends to conduct a single-arm, prospective, observational study of endoscopic sinus surgery for the treatment of soft tissue sarcoma of the nasal cavity and paranasal sinuses to explore the therapeutic effect and complications of endoscopic surgery for the treatment of soft tissue sarcoma of the nasal cavity and paranasal sinuses, and explore its relationship with chemotherapy and radiotherapy. The model of comprehensive treatment between.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Sign the informed consent form;
STS of nasal cavity and paranasal sinuses diagnosed pathologically;
General physical condition can tolerate endoscopic sinus surgery;
There is no distant transfer;
Disqualifiers
The patient has surgical contraindications: such as severe cardiopulmonary disease, coagulation dysfunction;
Suffer from uncontrolled concurrent diseases;
There is a serious neurological or mental illness, including dementia and epileptic seizures;
Uncontrolled active infection;
Trial population
For patients diagnosed with STS in the nasal cavity and paranasal sinuses through pathology, appropriate subjects will be selected according to the selection criteria and exclusion criteria of the protocol design.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
endoscopic surgery
Procedure/Surgerytransnasal endoscopic surgery
Treatment groups
40 Participants
are divided into 1 treatment groupGroup A: soft tissue sarcoma with endoscopic surgery1 intervention
Trial outcomes
Primary outcomes
1
overall survival
From the day of enrollment to death for any reason
Time frame
From date of enrollment until the date of death from any cause, whichever came first，through study completion,up to 5 years.Secondary outcomes
1
Local recurrence-free survival
The time from enrollment to local recurrence or death for any reason
Time frame
From date of first treatment until the date of local recurrence or the date of death from any cause,through study completion,up to 5 years.2
quality of life
The Chinese version of EORTC QLQ C30 questionnaire (V3.0)
Time frame
within 1 year after surgerySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov